Clinical trials, progression-speed differentiating features and swiftness rule of the innovative targets of first-in-class drugs
Yinghong Li(North China University of Science and Technology), Feng Zhu(Hebei Medical University), Weiwei Xue(Chongqing University), Fengcheng Li(Zhejiang University), Hong Yang(Second Military Medical University), Yu Jiang(Tsinghua University), Yu Chen(Shenzhen Bay Laboratory), Xiao Xu Li(Chongqing University), Yunxia Wang(Second Military Medical University), Chun Yan Yu(Chongqing University), Jianbo Fu(Zhejiang University), Jia Jun Hong(Zhejiang University), Jie Hu(Zhejiang University)
Cited by 158
Related Papers
Mechanisms of drug combinations: interaction and network perspectives
|Nature Reviews Drug Discovery|2009|954
Therapeutic target database 2020: enriched resource for facilitating research and early development of targeted therapeutics
|Nucleic Acids Research|2019|830
Therapeutic target database update 2022: facilitating drug discovery with enriched comparative data of targeted agents
|Nucleic Acids Research|2021|710
Comparative genetic architectures of schizophrenia in East Asian and European populations
|Nature Genetics|2019|709
HawkDock: a web server to predict and analyze the protein–protein complex based on computational docking and MM/GBSA
|Nucleic Acids Research|2019|646